Oragenics (OGEN)

• Market cap: $3.76M
• 1 day: -2.02%
• 5 days: -5.41%
• 1 month: -34.70%
• 3 months: -37.94%
• 6 months: -46.14%
• Year to date: -51.38%
• 1 year: -83.80%
• 5 years: -99.28%
• 10 years: -99.97%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Employees: 5

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 2

53% more funds holding

Funds holding: 15 [Q3] → 23 (+8) [Q4]

38% more capital invested

Capital invested by funds: $62.2K [Q3] → $86K (+$23.7K) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.03% less ownership

Funds ownership: 1.9% [Q3] → 1.87% (-0.03%) [Q4]